
Biostate AI is a biotechnology company revolutionizing healthcare through next-generation RNA sequencing and artificial intelligence. They have developed proprietary RNA sequencing technologies that drastically reduce costs by 50-70%, enabling large-scale data collection essential for AI-driven personalized medicine. Their integrated platform includes RNA sequencing services, AI-powered bioinformatics tools like OmicsWeb, Copilot, and QuantaQuill, which democratize complex data analysis for researchers without specialized expertise. Biostate AI aims to build the world's largest RNA sequencing database to train foundation AI models that predict disease outcomes and treatment responses, ultimately enabling personalized therapeutics. The company serves academic labs, pharmaceutical R&D, biobanks, clinical oncology research, and biotech startups, positioning itself as a leader in affordable, AI-enhanced molecular diagnostics with a global presence and strategic partnerships with top medical institutions.

Biostate AI is a biotechnology company revolutionizing healthcare through next-generation RNA sequencing and artificial intelligence. They have developed proprietary RNA sequencing technologies that drastically reduce costs by 50-70%, enabling large-scale data collection essential for AI-driven personalized medicine. Their integrated platform includes RNA sequencing services, AI-powered bioinformatics tools like OmicsWeb, Copilot, and QuantaQuill, which democratize complex data analysis for researchers without specialized expertise. Biostate AI aims to build the world's largest RNA sequencing database to train foundation AI models that predict disease outcomes and treatment responses, ultimately enabling personalized therapeutics. The company serves academic labs, pharmaceutical R&D, biobanks, clinical oncology research, and biotech startups, positioning itself as a leader in affordable, AI-enhanced molecular diagnostics with a global presence and strategic partnerships with top medical institutions.
Founded: 2023
Headquarters: Houston, TX
Core offering: Low-cost RNA sequencing wetlab + AI bioinformatics platform
Total funding: $16M
Notable lead investor: Accel (Series A, 2025)
Affordable, scalable multi-omics data generation and AI-driven interpretation for disease prediction, drug discovery, and clinical decision support.
2023
Biotechnology Research
$12M
Series A announced May 20–21, 2025
“Backed by institutional and high-profile individual investors including Accel, Caltech, Gaingels, Matter Venture Partners and individual backers such as Dario Amodei and Emily Leproust.”
| Company |
|---|